X0508 4 2023-07-18 0001842939 ALPHA HEALTHCARE ACQUISITION CORP III CTCX 0001984207 Hubbell Randolph W C/O CARMELL THERAPEUTICS CORPORATION 2403 SIDNEY STREET, SUITE 300 PITTSBURGH PA 15203 1 1 0 0 CEO & President 0 Stock Option (right to buy) 1.79 2023-07-14 4 A 0 217175 A 2027-06-20 Common Stock 217175 217175 D Stock Option (right to buy) 2.27 2023-07-14 4 A 0 37642 A 2029-07-19 Common Stock 37642 37642 D Stock Option (right to buy) 2.11 2023-07-14 4 A 0 480110 A 2031-09-23 Common Stock 480110 480110 D Options are fully vested and exercisable. Options to purchase 37,642 shares of common stock of Legacy Carmell (as defined below) granted on July 19, 2019, which vest as follows: 25% vested on July 19, 2020, July 19, 2021 and July 19, 2022. The remaining 25% will vest and become exercisable on July 19, 2023. Options to purchase 480,110 shares of common stock of Legacy Carmell granted on September 23, 2021, which vest as follows: 25% vested on September 23, 2022 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date. On July 14, 2023, Alpha Healthcare Acquisition Corp. III ("ALPA") consummated a business combination (the "Business Combination") by and among ALPA, Candy Merger Sub, Inc., a Delaware Corporation ("Merger Sub") and Carmell Regen Med Corporation, a Delaware corporation ("Legacy Carmell"), ALPA changed its name to "Carmell Therapeutics Corporation" and Merger Sub merged with and into Legacy Carmell. As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation. /s/ Randolph W. Hubbell 2023-07-18